Xerophthalmic Keratitis: A Complete Guide

What is Xerophthalmic keratitis?

Xerophthalmic keratitis (also spelled xerophthalmic keratitis) is an inflammation of the cornea that results from severe dryness of the ocular surface. The term combines three Greek roots: xero‑ (dry), ophthalmos (eye), and keratitis (corneal inflammation). When the tear film is insufficient or of poor quality, the corneal epithelium becomes damaged, leading to pain, visual disturbance, and, if untreated, permanent scarring.

Unlike infectious keratitis, which is caused by bacteria, viruses or fungi, xerophthalmic keratitis is a non‑infectious, mechanical injury driven by tear deficiency, abnormal eyelid function, or environmental factors that increase evaporation. It is frequently encountered in patients with dry‑eye disease, autoimmune disorders, or after ocular surgeries.

Common Causes

Several conditions can precipitate the dry‑eye environment that leads to xerophthalmic keratitis. The most important ones are listed below.

• Meibomian gland dysfunction (MGD) – obstructed or altered lipid glands reduce the tear‑film’s oily layer, causing rapid evaporation.
• Sjögren’s syndrome – an autoimmune disease that attacks the lacrimal and salivary glands, leading to severe aqueous‑tear deficiency.
• Blepharitis – chronic inflammation of the eyelid margins interferes with normal blinking and tear spreading.
• Contact lens wear – especially low‑oxygen‑permeable lenses, which impair tear exchange and can create micro‑trauma.
• Environmental exposure – windy, low‑humidity, or air‑conditioned environments increase tear evaporation.
• Medication‑induced dry eye – antihistamines, isotretinoin, antidepressants, and some antihypertensives reduce tear production.
• Ocular surgery – LASIK, cataract extraction, and ptosis repair can temporarily disrupt corneal nerves that stimulate tear reflexes.
• Systemic diseases – diabetes, rheumatoid arthritis, and thyroid eye disease can affect tear production or eyelid position.
• Neurotrophic keratitis – damage to corneal sensory nerves (e.g., after herpes zoster ophthalmicus) reduces blink reflex and tear secretion.
• Lacrimal gland obstruction or atrophy – congenital or acquired blockage reduces aqueous tear supply.

Associated Symptoms

Patients with xerophthalmic keratitis often report a cluster of ocular complaints that develop gradually.

• Burning, stinging, or gritty sensation (“like sand in the eye”).
• Redness (hyperemia) of the conjunctiva.
• Blurred vision that improves with blinking.
• Photophobia – discomfort in bright light.
• Excessive tearing (reflex tearing) paradoxically occurring because the eye tries to compensate for dryness.
• Foreign‑body sensation and the feeling of “rawness.”
• Upper or lower eyelid swelling and crusting.
• Reduced tear meniscus height visible on slit‑lamp exam.
• In advanced cases, white or greyish spots on the cornea (punctate epithelial erosions) that can coalesce into larger ulcers.

When to See a Doctor

Because the cornea is essential for clear vision, any persistent ocular discomfort warrants professional evaluation. Seek care promptly if you notice:

• Symptoms lasting more than a week despite over‑the‑counter lubricants.
• Marked eye redness that spreads beyond the corners.
• Sudden worsening of vision or new “foggy” spots.
• Sensitivity to light that does not improve with a hat or sunglasses.
• Discharge that is yellow, green, or foul‑smelling (possible secondary infection).
• History of recent eye surgery, trauma, or contact‑lens complications.

Early intervention can prevent permanent corneal scarring and vision loss.

Diagnosis

Ophthalmologists use a combination of patient history, visual‑inspection tools, and specialized tests to confirm xerophthalmic keratitis.

Clinical Examination

• Slit‑lamp biomicroscopy – the gold‑standard exam; reveals punctate epithelial erosions, tear‑film breakup time (TBUT) <5 seconds, and signs of meibomian gland dropout.
• Fluorescein staining – instilling fluorescein dye highlights areas where the epithelium is compromised (appears bright green).
• Lissamine green or Rose Bengal staining – stains devitalized cells on the conjunctiva and cornea, indicating ocular surface damage.
• Schirmer test – measures aqueous tear production using a small filter paper strip placed under the lower eyelid for 5 minutes.
• Tear osmolarity testing – elevated osmolarity (>308 mOsm/L) is a hallmark of dry‑eye disease.

Ancillary Testing (when needed)

• Meibography – infrared imaging of meibomian glands to evaluate dropout or obstruction.
• Ocular surface interferometry – assesses the lipid layer thickness.
• Corneal topography – helps rule out other causes of corneal irregularity.
• Blood tests – ANA, rheumatoid factor, or anti‑SSA/SSB antibodies if Sjögren’s syndrome is suspected.

Treatment Options

Management focuses on restoring a stable tear film, protecting the cornea, and addressing any underlying disease.

Artificial Tears & Lubricants

• Preservative‑free drops (e.g., Refresh® Optive, Systane® Ultra) used 4–6 times daily.
• Gel‑based lubricants or ointments at bedtime for prolonged moisture.

Anti‑Inflammatory Therapy

• Cyclosporine 0.05% ophthalmic emulsion (Restasis®) – improves tear production by modulating ocular surface inflammation.
• Lifitegrast 5% (Xiidra®) – reduces inflammatory cytokines and increases tear volume.
• Short courses of low‑potency corticosteroid drops (e.g., fluorometholone) for acute flare‑ups, under close supervision.

Secretagogue & Punctal Occlusion

• Oral lacrimal secretagogues such as pilocarpine or cevimeline for Sjögren’s patients.
• Punctal plugs (silicone or collagen) to block tear drainage and retain natural tears.

Meibomian Gland Therapy

• Warm compresses for 5–10 minutes, followed by gentle lid massage.
• Lipid‑based eyelid cleansers (e.g., Cliradex®, Blephaclean®).
• In‑office procedures: intense pulsed light (IPL) therapy or thermal pulsation (LipiFlow®).

Contact Lens Management

• Switch to high‑oxygen‑permeable silicone hydrogel lenses or discontinue use temporarily.
• Employ daily disposable lenses to reduce surface deposits.

Environmental & Lifestyle Modifications

• Use a humidifier (≥30% relative humidity) in dry indoor settings.
• Wear wrap‑around sunglasses outdoors to reduce wind‑evaporation.
• Avoid direct airflow from fans, air‑conditioners, or heating vents.
• Take regular “blink breaks” during computer work (20‑20‑20 rule).

When Secondary Infection Occurs

If bacterial or fungal superinfection is suspected, topical antibiotics (e.g., moxifloxacin) or antifungals are prescribed per culture results. Early treatment is crucial to prevent deeper stromal involvement.

Prevention Tips

While some risk factors (age, autoimmune disease) are unavoidable, many strategies can lessen the likelihood of xerophthalmic keratitis.

• Maintain eyelid hygiene. Daily warm compresses and gentle lid scrubs keep meibomian glands functional.
• Stay hydrated. Adequate systemic hydration supports tear production.
• Limit medications that dry the eyes. Discuss alternatives with your prescribing physician.
• Protect eyes from environmental stress. Use protective eyewear in windy or dusty conditions.
• Adopt a screen‑friendly routine. Blink consciously and use artificial tears before long screen sessions.
• Follow up with eye‑care professionals. Annual dry‑eye assessments help catch early changes before corneal damage.
• Manage systemic disease. Good control of diabetes, rheumatoid arthritis, or thyroid disease reduces ocular complications.

Emergency Warning Signs

Key Take‑aways

Xerophthalmic keratitis is a preventable and treatable condition when identified early. Understanding the underlying cause—whether it is inadequate tear production, meibomian gland dysfunction, or an external factor—guides effective therapy. Consistent use of preservative‑free lubricants, anti‑inflammatory drops, and eyelid care can restore ocular surface health. However, persistent symptoms, visual changes, or signs of infection must prompt prompt medical evaluation to avoid permanent corneal scarring.

References: Mayo Clinic – Dry Eye; CDC – Eye Health; NIH – Meibomian Gland Dysfunction Review; WHO – Eye Health Fact Sheet; Cleveland Clinic – Keratitis.